Alda-1 solution as well as preparation method and application thereof
The invention provides an Alda-1 solution as well as a preparation method and application thereof. According to the solution, Alda-1 is adopted as an active component, ethanol, polyethylene glycol 400and normal saline are adopted as solvents, and the problems that Alda-1 is poor in solubility and cannot be clinically used can be solved. The Alda-1 solution provided by the invention can be used asan injection for intravenous injection, heart functions can be well improved, in addition, the stability is good, the security is high, no hemolysis can be caused, and in addition, the solution has no conspicuous irritation to blood vessels in intravenous injection with dilution of the normal saline in a ratio of 1:1..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 15. Mai Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
CHEN YUGUO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-05-15, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111150704 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA00498966X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA00498966X | ||
| 003 | DE-627 | ||
| 005 | 20230504151017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210529s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA00498966X | ||
| 035 | |a (EPA)CN111150704 | ||
| 035 | |a (EPA)70562460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a CHEN YUGUO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alda-1 solution as well as preparation method and application thereof |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-05-15, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 | ||
| 520 | |a The invention provides an Alda-1 solution as well as a preparation method and application thereof. According to the solution, Alda-1 is adopted as an active component, ethanol, polyethylene glycol 400and normal saline are adopted as solvents, and the problems that Alda-1 is poor in solubility and cannot be clinically used can be solved. The Alda-1 solution provided by the invention can be used asan injection for intravenous injection, heart functions can be well improved, in addition, the stability is good, the security is high, no hemolysis can be caused, and in addition, the solution has no conspicuous irritation to blood vessels in intravenous injection with dilution of the normal saline in a ratio of 1:1. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHAI GUANGXI |4 aut | |
| 700 | 0 | |a XU FENG |4 aut | |
| 700 | 0 | |a WANG JIALI |4 aut | |
| 700 | 0 | |a ZHENG BOYUAN |4 aut | |
| 700 | 0 | |a FU MANFEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 15. Mai |
| 773 | 1 | 8 | |g year:2020 |g day:15 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/70562460/publication/CN111150704A1?q=CN111150704 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 15 |c 05 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 15 |c 05 | ||